Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PCV20 and cPCV7 in Japanese Adults
NCT03642847Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2018
- Primary completion
- Mar 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Prevnar 20 in pneumococcal disease (3 arms), sponsored by Pfizer. Primary endpoints: Prompted local reactions at 14 days, Prompted systemic events at 14 days and 3 more. Started Aug 2018; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT03642847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642847.